Elite Pharmaceuticals ( (ELTP) ) has released its Q1 earnings. Here is a breakdown of the information Elite Pharmaceuticals presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and distributing niche generic products, particularly oral, controlled-release drug products, operating from its cGMP and DEA-registered facility in Northvale, NJ.
In its latest earnings report for the first quarter of fiscal year 2026, Elite Pharmaceuticals announced a significant increase in revenue and operating profits, driven by the successful launch of its lisdexamfetamine products and robust growth in its existing product lines.
The company reported consolidated revenues of $40.2 million for the quarter ending June 30, 2025, marking a 114% increase compared to the same period last year. Operating profits surged by 462% to $21.7 million, largely due to the new product launch and strong performance of Elite’s label products.
Elite Pharmaceuticals’ management remains optimistic about future growth, emphasizing the impact of their strategic product launches and continued expansion of their generic product lines. The company plans to discuss these results and future developments in an upcoming conference call.